LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Aktien・Pulmatrix Inc

Pulmatrix Inc

Geschlossen

4.59 17.09

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.59

Max

4.68

Schlüsselkennzahlen
By Trading Economics
Einkommen	672K -877K
EPS	-0.24
Gewinnspanne	-60,266.667
Angestellte	2
EBITDA	671K -877K

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-3.3M 15M
Vorheriger Eröffnungskurs	-12.5
Vorheriger Schlusskurs	4.59

Pulmatrix Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Dez. 2025, 00:04 UTC

Akquisitionen, Fusionen, Übernahmen

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

12. Dez. 2025, 16:42 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

13. Dez. 2025, 16:48 UTC

Akquisitionen, Fusionen, Übernahmen

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13. Dez. 2025, 08:00 UTC

Akquisitionen, Fusionen, Übernahmen

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13. Dez. 2025, 07:00 UTC

Akquisitionen, Fusionen, Übernahmen

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13. Dez. 2025, 00:24 UTC

Akquisitionen, Fusionen, Übernahmen

Want a Piece Of SpaceX? -- Barrons.com

12. Dez. 2025, 23:49 UTC

Akquisitionen, Fusionen, Übernahmen

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12. Dez. 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12. Dez. 2025, 22:32 UTC

Ergebnisse

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Dez. 2025, 20:45 UTC

Ergebnisse

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12. Dez. 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12. Dez. 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12. Dez. 2025, 19:23 UTC

Ergebnisse

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12. Dez. 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12. Dez. 2025, 18:33 UTC

Akquisitionen, Fusionen, Übernahmen

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12. Dez. 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12. Dez. 2025, 17:49 UTC

Ergebnisse

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12. Dez. 2025, 17:34 UTC

Akquisitionen, Fusionen, Übernahmen

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12. Dez. 2025, 17:33 UTC

Akquisitionen, Fusionen, Übernahmen

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12. Dez. 2025, 17:33 UTC

Akquisitionen, Fusionen, Übernahmen

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12. Dez. 2025, 17:32 UTC

Akquisitionen, Fusionen, Übernahmen

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12. Dez. 2025, 17:31 UTC

Akquisitionen, Fusionen, Übernahmen

Orange to Buy the Stake for EU4.25B in Cash

12. Dez. 2025, 17:24 UTC

Market Talk

Argentina Predicts Record Wheat Crop -- Market Talk

12. Dez. 2025, 17:20 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

12. Dez. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Dez. 2025, 17:18 UTC

Market Talk

Ergebnisse

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12. Dez. 2025, 17:09 UTC

Market Talk

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12. Dez. 2025, 17:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12. Dez. 2025, 16:47 UTC

Market Talk

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

Peer-Vergleich

Kursveränderung

Pulmatrix Inc Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pulmatrix Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.